EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Tue, 15.10.2024
DocMorris AG
/ Key word(s): Quarterly / Interim Statement
DocMorris accelerates Rx growth
15.10.2024 / 06:58 CET/CEST
Frauenfeld, 15 October 2024
Press release
DocMorris accelerates Rx growth
Rx revenue growth of 12.2 per cent in the third quarter
Acceleration to over 25 per cent in the last few weeks
Strong incr...
Frauenfeld, 20 August 2024
Press release
Ad hoc announcement pursuant to Art. 53 LR
DocMorris grows in the prescription business and invests incrementally in new Rx customers
Sales of prescription medicines (Rx) grew year-on-year in July
Monthly number of new Rx customers quadrupled
Break-even achieved excluding eRx in the first half of 20...
DocMorris AG
/ Key word(s): Quarterly / Interim Statement
DocMorris with accelerated and significant eRx growth in new customers, market share and revenue
11.07.2024 / 06:58 CET/CEST
Frauenfeld, 11 July 2024
Press release
DocMorris with accelerated and significant eRx growth in new customers, market share and revenue ...
Frauenfeld, 23 May 2024
Press release
Ad hoc announcement pursuant to Art. 53 LR
Early redemption of the 2.75% Convertible Bonds due 2025
DocMorris Finance B.V. notifies the bondholders of its convertible bond due in 2025 that it has exercised the early redemption option
Notices to convert the Bonds may be deposited with the paying and conversi...
Frauenfeld, 23 May 2024
Press release
Ad hoc announcement pursuant to Art. 53 LR
Early redemption of the 2.75% Convertible Bonds due 2025
DocMorris Finance B.V. notifies the bondholders of its convertible bond due in 2025 that it has exercised the early redemption option
Notices to convert the Bonds may be deposited with the paying and conversi...
Please find our press release under the following link:https://ir-corporate.docmorris.com/en/investor-relations/convertible-bonds-2024
End of Inside Information
Language:
English
Company:
DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
ISIN:
CH0042615283
Listed:
SIX Swiss Exchange
EQS News ID:
1901981
End of Announceme...
Frauenfeld, 8 May 2024
Press release
Ad hoc announcement pursuant to Art. 53 LR
Daniel Wüest becomes new CFO at DocMorris
The Board of Directors of DocMorris AG has appointed Daniel Wüest to succeed Marcel Ziwica as CFO. Daniel Wüest will take over his new role on 1 October 2024.
Marcel Ziwica (49) will leave the company at his own request at...
Please find our press release under the following link:https://ir-corporate.docmorris.com/en/investor-relations/convertible-bonds-2024
End of Inside Information
Language:
English
Company:
DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
ISIN:
CH0042615283
Listed:
SIX Swiss Exchange
EQS News ID:
1895589
End of Announceme...
DocMorris AG
/ Key word(s): AGMEGM
Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich
02.05.2024 / 18:45 CET/CEST
Frauenfeld, 2 May 2024
Press release
Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich
The shareholders approved the annual rep...
Please find our press release under the following link:https://ir-corporate.docmorris.com/en/investor-relations/convertible-bonds-2024
End of Inside Information
Language:
English
Company:
DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
ISIN:
CH0042615283
Listed:
SIX Swiss Exchange
EQS News ID:
1892265
End of Announceme...
You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .